en Radiation Biology Radiation Biology تحقيق بديع Original Research <div style="text-align: justify;"><span style="font-size:10pt"><span style="text-justify:newspaper"><span style="text-kashida-space:50%"><span style="line-height:119%"><span style="font-family:Calibri"><span style="color:black"><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Background</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-GB" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-GB">To compare the efficacy as well as safety of hypofractionated radiotherapy (HFRT) with conventional fractionated radiotherapy (CFRT) for the treatment of early breast cancer (EBC) patients after breast-conserving surgery (BCS). </span></span></span></span><span lang="en-GB" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-GB">Materials and Methods: </span></span></span></span></span></span><span lang="en-GB" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-GB">Clinical data of 126 early breast cancer patients diagnosed and treated in our hospital from March 2021 to June 2023 were retrospectively analyzed. Patients were divided into HFRT group and CFRT group. The CFRT group accepted conventional segment radiotherapy. The HFRT group accepted hypofractionated radiotherapy. The clinical effect, breast beauty effect, incidence of adverse reactions, duration of hospital stay, local recurrence as well as distant metastasis in two groups were compared. </span></span></span></span><span lang="en-GB" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-GB">Results: </span></span></span></span></span></span><span lang="en-GB" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-GB">The HFRT and CFRT group showed no statistical difference in total response rate, breast beauty effect, length of hospital stay, local recurrence and distant metastasis rate (P>0.05). The incidence of bone marrow suppression, acute skin adverse reactions and radiation pneumonia in the HFRT group was lower than that in the CFRT group (P<0.05). The advanced skin adverse reactions were not statistically different between groups (P>0.05). </span></span></span></span><span lang="en-GB" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-GB">Conclusion: </span></span></span></span></span></span><span lang="en-GB" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-GB">Conventional radiotherapy and hypofractionated radiotherapy have similar clinical efficacy and safety for early breast cancer patients after BCS, while hypofractionated radiotherapy with the advantages of less radiotherapy times, short course of treatment and higher safety is valuable for clinical treatment.</span></span></span></span></span></span></span></span></span></span></div> Breast cancer, breast conserving surgery, hypofractionated radiotherapy. 163 168 http://ijrr.com/browse.php?a_code=A-10-1-1306&slc_lang=en&sid=1 J. Tang jiangxtjl350@163.com 7900319475328460029587 7900319475328460029587 Yes Department of Oncology, Pingxiang People’s Hospital, Pingxiang, Jiangxi 337055, China X. Xu 7900319475328460029588 7900319475328460029588 No Department of Oncology, Pingxiang People’s Hospital, Pingxiang, Jiangxi 337055, China M. Chen 7900319475328460029589 7900319475328460029589 No Department of Oncology, Pingxiang People’s Hospital, Pingxiang, Jiangxi 337055, China L. Liu 7900319475328460029590 7900319475328460029590 No Department of Oncology, Pingxiang People’s Hospital, Pingxiang, Jiangxi 337055, China Z. Zhan 7900319475328460029591 7900319475328460029591 No Department of Oncology, Pingxiang People’s Hospital, Pingxiang, Jiangxi 337055, China